Athira Pharma (NASDAQ:LONA) Posts Earnings Results

Athira Pharma (NASDAQ:LONA) issued its earnings results on Thursday. The company reported ($18.90) EPS for the quarter, FiscalAI reports.

Athira Pharma Stock Down 7.3%

LONA opened at $8.97 on Friday. Athira Pharma has a 1 year low of $2.20 and a 1 year high of $14.21. The firm has a market capitalization of $35.34 million, a P/E ratio of -0.93 and a beta of 2.68.

Analyst Ratings Changes

Several brokerages have issued reports on LONA. Mizuho raised Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Thursday, February 19th. Cantor Fitzgerald assumed coverage on shares of Athira Pharma in a report on Thursday, February 26th. They issued an “overweight” rating on the stock. Weiss Ratings assumed coverage on shares of Athira Pharma in a research report on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Zacks Research upgraded shares of Athira Pharma to a “hold” rating in a research note on Friday, February 27th. Finally, Wall Street Zen downgraded shares of Athira Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Athira Pharma presently has an average rating of “Hold” and a consensus target price of $10.00.

Insiders Place Their Bets

In related news, CEO Mark James Litton sold 5,156 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $5.37, for a total transaction of $27,687.72. Following the transaction, the chief executive officer directly owned 57,926 shares of the company’s stock, valued at approximately $311,062.62. This trade represents a 8.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 9,110 shares of company stock worth $48,921. 25.07% of the stock is owned by company insiders.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.